BRIEF-AstraZeneca Says Symbicort Approved In China For Mild Asthma
AstraZeneca PLC:
* ASTRAZENECA PLC - SYMBICORT APPROVED IN CHINA FOR MILD ASTHMA
* ASTRAZENECA - SYMBICORT TURBUHALER BECOMES FIRST DUAL-COMBINATION THERAPY APPROVED IN CHINA FOR MILD, MODERATE AND SEVERE ASTHMA Source text for Eikon: Further company coverage:
ALSO READ
-
ILO Report Reveals How to Bring Social Security Within Reach of Informal Workers
-
WTO Sets Up Panel on EU Carbon Border Rules as Russia Challenges Restrictions
-
WHO Brings Global Experts Together to Strengthen Herbal Medicine Quality and Safety
-
Human Cost of Faster Work: Chinese Employees Weigh AI’s Promise Against Pay Fears
-
China's August Disasters Yield $5.38 Billion in Losses
Google News